Larvol Delta - Comparative-Effectiveness-of-Risankizumab-Versus-Tumour-Necrosis-Factor-Inhibitors-or-Interleukin17-Inhibitors-on-Joint-Outcomes-in-BiologicNa239ve-Patients-With-Psoriatic-Arthritis-A-Global-RealWorld-Study

Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim

https://eppro02.ativ.me/web/page.php?nav=false&page=Session&project=ACR26&id=3570216

Philip Mease, MD

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next